Sanlorenzo S.p.A. (MUN:6SZA)
| Market Cap | 1.19B |
| Revenue (ttm) | 1.03B |
| Net Income (ttm) | 107.42M |
| Shares Out | n/a |
| EPS (ttm) | 3.04 |
| PE Ratio | 11.11 |
| Forward PE | 11.33 |
| Dividend | 1.50 (4.34%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | 200 |
| Average Volume | 83 |
| Open | 34.60 |
| Previous Close | 32.20 |
| Day's Range | 34.60 - 34.60 |
| 52-Week Range | 30.35 - 34.60 |
| Beta | n/a |
| RSI | 53.80 |
| Earnings Date | May 8, 2026 |
About Sanlorenzo
Sanlorenzo S.p.A. designs, builds, and sells boats and pleasure boats in Italy, rest of Europe, the Asia-Pacific, the United States, the Middle East, and internationally. It operates through four divisions: Yacht, Superyacht, Bluegame, and Nautor Swan. The company provides maintenance and charter services for various vessels, as well as sells its new and pre-owned yachts. It also designs, manufactures, and markets motor, super, sport utility, and sailing yachts under the Sanlorenzo and Bluegame brands. The company was formerly known as Cantieri... [Read more]
Financial Performance
In 2025, Sanlorenzo's revenue was 1.03 billion, an increase of 4.16% compared to the previous year's 986.00 million. Earnings were 107.42 million, an increase of 4.17%.
News
Sanlorenzo Earnings Call Transcript: Q4 2025
Revenue grew 3.2% to EUR 960.4 million with net profit up 4.2% and a robust 18.8% EBITDA margin. Order intake rose 16%, backlog exceeds EUR 2 billion, and integration of Nautor Swan and Simpson Marine drove growth, especially in Americas and APAC.
Sanlorenzo Earnings Call Transcript: Q4 2025
Full-year 2025 saw resilient growth, with revenue up 3.2% and net profit rising 4.2% year-on-year, driven by strong order intake, new model launches, and global expansion. Early 2026 order trends are positive, with robust backlog and plans for further production capacity.
Sanlorenzo Earnings Call Transcript: Q3 2025
Sustained growth in 2025 with net revenue up 3.2% and net profit up 4.1% year-on-year, driven by strong order intake, new model launches, and robust performance in Europe and the Americas. Guidance for 2025 is confirmed, with high visibility into 2026 and beyond.
Sanlorenzo Earnings Call Transcript: Q2 2025
Net revenue grew 9.4% year-over-year to €454.1M, with EBITDA up 8.5% and net profit up 7%. Order intake surged 30% year-over-year, and backlog remains robust, supporting confirmed 2025 guidance. New product launches and direct distribution expansion drive future growth.
Sanlorenzo Earnings Call Transcript: Q1 2025
Q1 2025 delivered strong growth with net revenue up 9.6% and net profit up 80% year-over-year, driven by Superyacht and Nautos One divisions. Backlog remains robust, covering 71% of 2025 guidance, and management confirmed the outlook despite U.S. tariff uncertainties.
Sanlorenzo Earnings Call Transcript: Q4 2024
2024 saw double-digit revenue and profit growth, led by the Superyacht Division and strong performance in the Americas and Middle East. Conservative 2025 guidance reflects geopolitical uncertainty, but a robust backlog and new product launches support continued stability and growth.
Sanlorenzo Earnings Call Transcript: Q4 2024
Full-year 2024 saw double-digit revenue and EBITDA growth, strong backlog, and successful integration of acquisitions. Market normalization continues, with robust performance in the Americas and MEA, and new sustainability initiatives and product lines set to drive future growth.
Sanlorenzo Earnings Call Transcript: Q3 2024
Q3 2024 saw strong revenue and profit growth, record backlog, and robust performance across divisions, with guidance confirmed despite geopolitical headwinds. Accelerated net working capital reabsorption and strategic acquisitions support future growth, while order intake remains solid.
Sanlorenzo Earnings Call Transcript: Q2 2024
H1 2024 saw 6.9% revenue growth and 11.6% net profit increase, with strong Superyacht and Bluegame performance. The Swan acquisition added double-digit EBITDA margin and a €160 million backlog, while the order book remains robust and guidance for 2024 is confirmed.